What a ChondroFiller injection costs in the UK

ChondroFiller injection in the UK is priced on a fixed tier model based on the volume of collagen scaffold required, which in turn reflects the area of the cartilage defect being treated.

| Boxes required | Defect area covered | Price | |---|---|---| | 1 box | ~3 cm² | £3,000 | | 2 boxes | ~4.5 cm² | £5,500 | | 3 boxes | ~6 cm² | £8,000 | | Complex / multi-compartment | — | Up to £9,800 |

Each tier is fully all-inclusive: the initial consultation, real-time ultrasound guidance, the collagen scaffold product itself, the injection procedure, and a six-week clinical follow-up are all covered within that single figure. Nothing is billed separately. The same pricing structure applies regardless of which joint is being treated — knee, hip, ankle, shoulder, elbow, or wrist.

The dominant cost within the all-in price is the ChondroFiller product itself — a CE-marked Class III collagen scaffold imported from Germany under prescription. That product cost holds constant whether it is placed into a knee or a wrist, which is why the tier model is driven by defect size rather than joint location.

Most patients presenting with a standard focal cartilage defect require only one box. For the majority, the relevant figure is therefore £3,000 — and that is the reference point used throughout the rest of this article.

What the price actually includes

The outpatient delivery model is what removes the secondary costs most patients associate with any cartilage procedure. Because ChondroFiller injection is administered in a clinic room under local anaesthesia or mild sedation — not in an operating theatre — there is no consultant anaesthetist's fee, no theatre-booking charge, and no overnight facility cost. The procedure itself takes approximately 30–45 minutes, and patients are discharged the same day.

Ultrasound guidance is worth noting as a clinical inclusion rather than simply a billing one: real-time imaging during scaffold placement allows the clinician to position the collagen gel precisely within the defect and verify fill in the same session, rather than relying on pre-procedure landmarks alone.

For self-paying patients, the tier price is the total cost — no additional line items should appear. Those pursuing private insurance reimbursement are in a different position: insurers typically authorise individual CCSD codes rather than bundled episode prices, so it is worth confirming the specific components your insurer will recognise before booking, rather than assuming the bundled figure maps cleanly to a policy.

How ChondroFiller injection compares to cartilage surgery costs

Against the surgical end of the UK private cartilage repair market, the cost gap at entry level is considerable. Standard surgical repair — including AMIC, scaffold-augmented procedures, and arthroscopic keyhole techniques — starts at around £9,800 for the knee at London Cartilage Clinic, roughly three times the cost of a one-box ChondroFiller injection. Across UK private centres more broadly, knee cartilage repair surgery typically falls between £7,000 and £14,000, though what each clinic bundles into that figure varies considerably: some include anaesthetist fees and post-operative physiotherapy; others do not.

The full UK private cartilage repair cost spectrum looks like this:

• ChondroFiller injection, one box: £3,000 (most patients with a focal defect)
• ChondroFiller injection, two to three boxes / complex: £5,500–£9,800
• AMIC / scaffold-augmented arthroscopic repair (knee): from ~£7,000–£9,800
• OATS / Mosaicplasty: approximately £14,000
• STACi (single-stage ACI) / Osteochondral Allograft (OCA): approximately £28,000

Non-knee surgical repair carries an approximate 30% uplift to reflect access complexity, putting non-knee procedures from around £12,740 upwards.

At the upper end of the ChondroFiller injection range — three boxes or a complex multi-compartment case at £8,000–£9,800 — the price sits alongside rather than clearly below entry-level surgical options. At that point, the choice between pathways is a clinical question far more than a financial one.

Microfracture, while historically positioned as a lower-cost surgical entry point, is now in declining use. Evidence has consistently shown fibrocartilage breakdown at two to three years, with secondary damage to the subchondral bone plate that can limit future repair options — which makes cost the least relevant factor when weighing it against alternatives.

Throughout this spectrum, technique suitability is determined by defect grade, defect size, bone involvement, and clinical assessment. Price position alone is not a reliable guide to which approach is appropriate.

NHS access and private insurance

ChondroFiller injection has no NHS commissioning pathway and is not available through public funding. All access is via private clinics, and self-paying patients do not need a GP referral — a direct booking with the London Cartilage Clinic is straightforward.

Private health insurance coverage is possible, but patients should treat it as a realistic possibility rather than an expectation. Bupa, Aviva, and WPA are the insurers most commonly reported to have approved claims, though approvals are discretionary, assessed case-by-case, and governed by individual policy terms. Coverage rates are anecdotal; what one policyholder's Bupa plan covered, another's may not.

For those pursuing the insurance route, the practical steps matter:

• Contact your insurer before booking, not after.
• Request written pre-authorisation for the procedure. Retrospective claims — submitted once the treatment is already done — are unlikely to succeed.
• Supply the relevant CCSD billing codes: W3111 (cartilage regeneration with collagen scaffold) and W8500 (image-guided procedure). These are the codes under which ChondroFiller injection is typically billed.
• Ask your insurer explicitly whether it will recognise a bundled episode price or authorise the component codes individually, as this affects how the clinic can submit your claim.

If your insurer declines or your policy does not include this category of treatment, the fixed-tier self-pay pricing described above applies in full.

Secondary costs that surgery adds and injection avoids

Quoted surgical prices rarely capture the full financial picture. A headline figure of £9,800 for keyhole cartilage repair may not include the consultant anaesthetist's fee or the theatre facility charge — both inherent to a procedure requiring general or spinal anaesthesia and 90–120 minutes of operating time. Post-operative physiotherapy is clinically necessary across a recovery spanning up to two years but is rarely bundled into the surgical quote. Patients in employment should also factor several weeks of work absence into any cost calculation; for the self-employed, lost income is a direct variable with no fixed value.

ChondroFiller injection's one-to-two-week return-to-activity window stands in clear contrast: no theatre, no consultant anaesthetist, no staged rehabilitation programme.

Patients with more complex joint presentations — Kellgren-Lawrence Grade III/IV osteoarthritis, for instance — may sit outside the standard focal-defect indication and instead be offered a combination injection protocol. A ChondroFiller-plus-Arthrosamid protocol costs £6,000; a tri-active protocol adding autologous mesenchymal stem cells reaches £11,000. The two products serve different roles: ChondroFiller is the regenerative scaffold, Arthrosamid a non-regenerative hydrogel that acts on the joint environment by a separate mechanism. Even at the upper combination tier, these figures sit below or alongside mid-range surgical alternatives — though the underlying patient populations differ and direct comparisons have limits.

No published cost-effectiveness modelling yet maps injection against surgery across a patient's lifetime, accounting for factors such as the possibility of a repeat injection or eventual surgical intervention. The secondary costs described above are real and documentable; how much weight any individual patient should place on them will depend on their employment situation, insurer cover, and clinical pathway.

Getting an accurate cost for your case

Price, ultimately, is the easiest variable to know in advance. What the quoted figures cannot tell a patient is which tier applies to their specific defect — that requires imaging to establish the area and depth of the lesion, and a clinical assessment to determine whether more than one compartment is involved. A patient assuming they fall into the one-box, £3,000 tier may be correct; they may equally require two boxes once the defect is properly characterised. The tier is set by anatomy, not by preference.

The second question that deserves space at assessment is outcomes rather than just cost. Across the published ChondroFiller evidence base, 70–85% of treated patients achieve meaningful symptom relief at three to five years — a useful orientation, though the figure spans a range of joint sites and defect profiles and does not come from a single definitive trial. What that means for an individual depends on lesion grade, joint load, and how precisely the scaffold is placed. Technique plays a meaningful role alongside product selection: image-guided placement demands a level of procedural experience that varies between practitioners.

Liquid Cartilage™ is delivered in the UK at the London Cartilage Clinic on Harley Street, where Professor Paul Y. F. Lee leads the ChondroFiller injection programme. Clinical assessments can be booked directly at londoncartilage.com.